Anti-FRalpha Fab Nanomolar Affinity Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-FRalpha therapeutics, such as monoclonal antibodies, have shown limited efficacy in treating cancers that overexpress folate receptor alpha (FRalpha), with previous candidates like farletuzumab failing to meet primary endpoints in clinical trials.
Innovation Solution
Development of a novel anti-FRalpha Fab with complementarity determining regions (CDRs) that exhibit nanomolar affinity for FRalpha, retaining this affinity in IgG formats and allowing for pre-clinical development as a cancer immunotherapeutic.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used to target FRalpha, then the therapeutic approach is established, but the efficacy is limited and clinical trials fail to meet primary endpoints
Solution Approach 1:
The patent applies parameter changes by optimizing the affinity of the antibody to FRalpha from conventional levels to nanomolar range (KD < 10^-9 M). This significant improvement in binding affinity parameter directly addresses the limited efficacy of previous therapeutics and enables the antibody to effectively target and internalize FRalpha on cancer cells, thereby improving therapeutic reliability and clinical potential
2Manufacturing precision
If high affinity binding is achieved, then targeting effectiveness improves, but the complexity of developing novel CDRs increases
Solution Approach 1:
The patent applies segmentation by focusing on the critical CDR regions (CDR1, CDR2, CDR3 of heavy chain and light chain) as the key functional segments that determine binding affinity. By identifying and optimizing these specific segments rather than the entire antibody structure, the patent achieves nanomolar affinity while managing design complexity through targeted modification of only the essential binding regions
Solution Approach 2:
The patent changes the binding affinity parameter to nanomolar range through systematic optimization of CDR sequences. This parameter change is achieved by evaluating multiple CDR combinations and selecting those that provide the optimal balance between high affinity and manageable design complexity, as evidenced by the specific CDR sequences disclosed that achieve KD < 10^-9 M
3Reliability
If novel CDRs are developed with nanomolar affinity, then therapeutic potential increases, but pre-clinical development time and resources are required
Solution Approach 1:
The patent applies preliminary action by performing comprehensive in vitro characterization of the novel CDRs before advancing to pre-clinical studies. The CDRs are first evaluated for binding affinity (nanomolar KD), specificity to FRalpha, and ability to induce internalization in controlled laboratory settings. This preliminary validation ensures therapeutic potential is confirmed early, reducing the risk of failure later and optimizing the use of pre-clinical development time and resources
Data Source
AI summary
This disclosure describes nucleic acids that encode proteins that specifically bind human folate receptor alpha (FRalpha) with high affinity. These proteins include a recombinant human anti-FRalpha IgG1 that is suitable for use as a therapeutic antibody to treat cancers that express FRalpha. Other FRalpha-binding proteins are also described including antibody fragments, antibody conjugates, and fusion proteins.